S& P 500 hits all time highs U.S.-Japan trade deal optimism
Investing.com -- Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) stock jumped 3.8% following positive Phase 3 efficacy results for its seasonal influenza vaccine candidate, which demonstrated superior effectiveness compared to standard flu vaccines.
The company’s mRNA-1010 vaccine achieved a relative vaccine efficacy of 26.6% against influenza illness in adults aged 50 years and older when compared to licensed standard-dose seasonal influenza vaccines. The trial showed strong efficacy across all influenza strains contained in the vaccine, with 29.6% efficacy against A/H1N1, 22.2% against A/H3N2, and 29.1% against B/Victoria lineages.
"Today’s strong Phase 3 efficacy results are a significant milestone in our effort to reduce the burden of influenza in older adults. The severity of this past flu season underscores the need for more effective vaccines," said Stéphane Bancel, Chief Executive Officer of Moderna.
The Phase 3 study enrolled 40,805 adults aged 50 years and older across 11 countries. Participants received either a single dose of mRNA-1010 or a standard-dose licensed comparator, with a median follow-up of six months. In participants aged 65 years and older, the vaccine demonstrated a relative efficacy of 27.4%.
Safety and tolerability of mRNA-1010 were consistent with previous studies, with most solicited adverse reactions being mild. Injection site pain was the most common local reaction, while fatigue, headache, and myalgia were the most common systemic reactions reported.
The company plans to present the data at an upcoming medical conference and submit for peer-reviewed publication. Moderna will also engage with regulators on filing submissions for mRNA-1010.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.